Target intelligence / Profile preview

Testin LIM domain protein (TES)

Target
TES
Molecular classification
LIM domain protein family (zinc-finger protein), Cytoskeletal scaffold protein, Protein-protein interaction motif protein, Not a receptor, enzyme, transporter, or transcription factor.
01

Overview

Testin LIM domain protein is a cytoskeletal scaffold and signaling integrator found at focal adhesions and along actin stress fibers, encoded by the TES gene. It is characterized by three C-terminal LIM domains and a PET domain, allowing for versatile protein-protein associations. Testin promotes cell adhesion, cytoskeleton maintenance, and suppresses tumorigenesis. It is mainly studied in cancer biology, as its loss leads to disrupted cell structure and increased metastatic capacity. Testin interacts with zyxin, actin, MENA (ENAH), VASP, alpha-actinin, paxillin, talin, ALKBH4, GRIP1 and other focal adhesion partners, mediating its function as a tumor suppressor[1][5][6][7].\n\nTestin LIM domain protein is not a classic receptor, enzyme, transporter, or transcription factor, but belongs to the LIM domain scaffold/cytoskeletal regulators, and is characterized primarily as a tumor suppressor with important roles in cellular structure, adhesion, and cancer pathophysiology[1][2][5][6].

Other names
TESTESSTESS-2TESTIN
02

Mechanism of action

No drugs directly targeting TES; hypothetical/experimental mechanisms would involve mimicking TES's interaction with MENA to inhibit cancer cell motility[1].

03

Biological functions

Cell adhesionCell spreadingCytoskeleton organizationRegulation of cell proliferationTumor suppressionApoptosisCell migration
04

Disease associations

Cancer (tumor suppressor in multiple malignancies; such as breast, prostate, colorectal, gastric)Cancer metastasis (role in cell motility and adhesion)Testicular germ cell tumor (non-seminomatous)
05

Safety considerations

No direct safety concerns described for TES targeting; as a tumor suppressor, loss of function increases cancer risk[1][6]Therapeutic challenges include restoring expression or mimicking function in tumor settings.
06

Biomarkers

TES downregulation can serve as a biomarker for cancer and cancer metastasis risk[6]Methylation of the TES promoter is a potential marker for gene silencing in cancers[1]

Beyond the preview

Go deeper on Testin LIM domain protein (TES).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Testin LIM domain protein (TES).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call